Drug Type Small molecule drug |
Synonyms Hemi L-glutarate salt of 7-[(3R,4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5- dihydro-pyrrolo [3,2-d] pyrimidin-4-one, LR 09, LR-09 + [1] |
Target |
Action inhibitors |
Mechanism PNP inhibitors(Purine nucleoside phosphorylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Leukemia | Preclinical | Canada | 01 Sep 2025 | |
Acute Lymphoblastic Leukemia | Preclinical | Switzerland | 14 Dec 2022 |